Pharvaris
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Pharvaris and other ETFs, options, and stocks.About PHVS
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases.
CEOBerndt A. E. Modig
CEOBerndt A. E. Modig
Employees108
Employees108
HeadquartersLeiden, Zuid-Holland
HeadquartersLeiden, Zuid-Holland
Founded2015
Founded2015
Employees108
Employees108
PHVS Key Statistics
Market cap1.54B
Market cap1.54B
Price-Earnings ratio-7.36
Price-Earnings ratio-7.36
Dividend yield—
Dividend yield—
Average volume723.25K
Average volume723.25K
High today$24.13
High today$24.13
Low today$23.45
Low today$23.45
Open price$23.69
Open price$23.69
Volume226.14K
Volume226.14K
52 Week high$29.80
52 Week high$29.80
52 Week low$11.51
52 Week low$11.51
Stock Snapshot
Pharvaris(PHVS) stock is priced at $24.05, giving the company a market capitalization of 1.54B. It carries a P/E multiple of -7.36.
On 2025-12-11, Pharvaris(PHVS) stock traded between a low of $23.45 and a high of $24.13. Shares are currently priced at $24.05, which is +2.6% above the low and -0.3% below the high.
The Pharvaris(PHVS)'s current trading volume is 226.14K, compared to an average daily volume of 723.25K.
In the last year, Pharvaris(PHVS) shares hit a 52-week high of $29.80 and a 52-week low of $11.51.
In the last year, Pharvaris(PHVS) shares hit a 52-week high of $29.80 and a 52-week low of $11.51.
Analyst ratings
92%
of 12 ratingsBuy
91.7%
Hold
8.3%
Sell
0%
People also own
Based on the portfolios of people who own PHVS. This list is generated using Robinhood data, and it’s not a recommendation.